MA 07.03 Incidence, Predictors and Prognostic Significance of Thromboembolic Events in Patients with Advanced Alk-Rearranged NSCLCs

Zugazagoitia, Jon; Biosca, María Eugenia Alonso; Grau, Jaume; Olivera, J.; Bei, Lu; Olmedo, María Eugenia; Rueda, A. Gómez; Muñóz, Núbia; Ponce, Santiago; Dómine, Manuel; Zenzola, Victor; Nadal, Ernest; Ruffinelli, J.C.; Luna, A.M. Castro; Hernández, Berta; Martínez, Maite; Font, Carme; García-Morillo, Marcial; Gallego, Iria; Cabrero, D. Sánchez; Miranda, Jesús; Castro, Eva Martínez de; Cacho, Juan Diego; Calvo, V.; Martínez, J.; Noguerón, Esther; Mondéjar, Rebeca; Escobar, Ignacio; Salvador-Coloma, C.; Juan, Óscar; Cánovas, Manuel Sánchez; Valdivia, Javier; Ochoa, Manuel; Castro, R. López; Obispo, Berta; Pangua, Cristina; Sereno, María; Franco, L. Fernández; Mielgo, Xabier; Calzas, Julia; Blasco, Ana; Aparisi, Francisco; Chara, L.E.; Lora, David; Muñoz, Andrés; Paz‐Ares, Luis; Manzano, Aránzazu

doi:10.1016/j.jtho.2017.09.505

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two prior retrospective cohort studies of 264 and 99 ALKþ lung cancer patients reported a TEE incidence of 30% and 36%, respectively, much higher than historically reported rates in the general lung cancer population. 12,13 Although our study reported a shorter period of follow-up for TEEs, it also reproduced the observation that ALKþ patients are at increased risk of developing TEEs.…”

Section: Discussionsupporting

confidence: 87%

“…Despite prior studies showing an association between cancer-associated thrombosis and worse survival, our study did not show worse survival in the subgroups that developed a TEE, both in the overall study cohort and across molecular driver groups. 6,12 Possible reasons for this different observation include insufficient duration of follow-up and potentially insufficient sample size. Considering the prolonged disease control feasible from targeted therapies among ROSþ, ALKþ, and EGFRþ patients, it is also possible that subsequent TEE propensity and its associated risks on survival may be abrogated by highly active anti-cancer therapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events

Ng¹,

Smith

Mushtaq³

et al. 2019

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Introduction: This study aims to determine whether advanced ROS1 gene-rearranged NSCLC (ROS1þ NSCLC) has a higher than expected thromboembolic event (TEE) rate.Methods: Venous and arterial TEEs within ±365 days of diagnosis of ROS1þ, ALKþ, EGFRþ, or KRASþ advanced NSCLC at five academic centers in the United States and China were captured (October 2002-April 2018). The primary endpoint was incidence of TEE in ROS1þ compared to anaplastic lymphoma kinase (ALK)þ, EGFRþ, and KRASþ NSCLC within ±90 days of diagnosis. Logistic regression was used to assess if the odds of TEE differed among oncogene drivers.Results: Eligible data from 95 ROS1þ, 193 ALKþ, 300 EGFRþ, and 152 KRASþ NSCLC patients were analyzed. The incidence rate of TEE was 34.7% (n ¼ 33), 22.3% (n ¼ 43), 13.7% (n ¼ 41), and 18.4% (n ¼ 28), respectively. In univariate analysis, the odds of a TEE in ROS1þ NSCLC were higher than ALKþ, EGFRþ, and KRASþ cohorts. In multivariable analysis, the odds of a TEE were significantly higher for ROS1þ compared to EGFRþ and KRASþ cohorts, the odds ratio (OR) was 2.44, with a 95% confidence interval of 1.31-4.57 (p ¼ 0.005), and OR: 2.62, with a 95% confidence interval of 1.26-5.46 (p ¼ 0.01), respectively.Although numerically superior, the odds for a TEE with ROS1þ compared to ALKþ was not statistically significant (OR: 1.45, p ¼ 0.229). Overall survival was not significantly

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%